Minimal change disease and idiopathic FSGS: manifestations of the same disease

被引:131
作者
Maas, Rutger J. [1 ]
Deegens, Jeroen K. [1 ]
Smeets, Bart [2 ]
Moeller, Marcus J. [3 ]
Wetzels, Jack F. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Nephrol, Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, POB 9101, NL-6500 HB Nijmegen, Netherlands
[3] Rhein Westfal TH Aachen, Univ Hosp, Dept Nephrol & Clin Immunol, Pauwelsstr 30, D-52074 Aachen, Germany
关键词
FOCAL-SEGMENTAL GLOMERULOSCLEROSIS; SOLUBLE UROKINASE RECEPTOR; LONG-TERM PROGNOSIS; NEPHROTIC-SYNDROME; PERMEABILITY FACTORS; LIPOID NEPHROSIS; PUROMYCIN AMINONUCLEOSIDE; HISTOLOGICAL VARIANTS; PODOCYTE DEPLETION; GENE-EXPRESSION;
D O I
10.1038/nrneph.2016.147
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are the key histological findings in patients with idiopathic nephrotic syndrome (INS). Although MCD and idiopathic FSGS are often considered to represent separate entities based on differences in their presenting characteristics, histology and outcomes, little evidence exists for this separation. We propose that MCD and idiopathic FSGS are different manifestations of the same progressive disease. The gradual development of FSGS in patients with non-remitting or relapsing INS has been well documented. Moreover, FSGS is the uniform result of substantial podocyte loss in animal models, and a common feature of virtually all progressive human glomerulopathies. As evidence suggests a common aetiology, the pathogenesis of MCD and idiopathic FSGS should be studied together. In clinical trials, idiopathic FSGS should be considered to represent an advanced stage of disease progression that is less likely to respond to treatment than the earlier stage of disease, which is usually defined as MCD.
引用
收藏
页码:768 / 776
页数:9
相关论文
共 128 条
[2]  
[Anonymous], 1978, KIDNEY INT, V13, P159
[3]  
Appel G. B., 2010, COMPREHENSIVE CLIN N, P229
[4]   T regulatory cell function in idiopathic minimal lesion nephrotic syndrome [J].
Araya, Carlos ;
Diaz, Leila ;
Wasserfall, Clive ;
Atkinson, Mark ;
Mu, Wei ;
Johnson, Richard ;
Garin, Eduardo .
PEDIATRIC NEPHROLOGY, 2009, 24 (09) :1691-1698
[5]   PLASMAPHERESIS REDUCES PROTEINURIA AND SERUM CAPACITY TO INJURE GLOMERULI IN PATIENTS WITH RECURRENT FOCAL GLOMERULOSCLEROSIS [J].
ARTERO, ML ;
SHARMA, R ;
SAVIN, VJ ;
VINCENTI, F .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 23 (04) :574-581
[6]   Time course of proteinuria after living-donor kidney transplantation [J].
Artz, MA ;
Dooper, PMM ;
Meuleman, EJH ;
van der Vliet, JA ;
Wetzels, JFM .
TRANSPLANTATION, 2003, 76 (02) :421-423
[7]   Upregulation of Nuclear Factor-Related Kappa B Suggests a Disorder of Transcriptional Regulation in Minimal Change Nephrotic Syndrome [J].
Audard, Vincent ;
Pawlak, Andre ;
Candelier, Marina ;
Lang, Philippe ;
Sahali, Djillali .
PLOS ONE, 2012, 7 (01)
[8]   RENAL PATHOLOGY OF FETUSES WITH CONGENITAL NEPHROTIC SYNDROME OF THE FINNISH TYPE - A QUALITATIVE AND QUANTITATIVE LIGHT MICROSCOPIC STUDY [J].
AUTIOHARMAINEN, H ;
RAPOLA, J .
NEPHRON, 1981, 29 (3-4) :158-163
[9]   Decreased expression of T-cell NF-κB p65 subunit in steroid-resistant nephrotic syndrome [J].
Aviles, DH ;
Vehaskari, VM ;
Manning, J ;
Ochoa, AC ;
Zea, AH .
KIDNEY INTERNATIONAL, 2004, 66 (01) :60-67
[10]   Altered activity of plasma hemopexin in patients with minimal change disease in relapse [J].
Bakker, WW ;
van Dael, CML ;
Pierik, LJWM ;
van Wijk, JAE ;
Nauta, J ;
Borghuis, T ;
Kapojos, JJ .
PEDIATRIC NEPHROLOGY, 2005, 20 (10) :1410-1415